Compare Bristol-Myers Squibb Co (BMY) vs Levi Strauss & Co. (LEVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Levi Strauss & Co. — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while Levi Strauss & Co. trades at $23.72 (market cap $9.16B). The key difference: Bristol-Myers Squibb Co is far larger — about 12.7× Levi Strauss & Co.'s market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | LEVI | |
|---|---|---|
Market Cap | $116.30B | $9.16B |
Sector | Health | Consumer Cyclical |
52-Week High | $62.37 | $24.83 |
52-Week Low | $42.60 | $17.92 |
Enterprise Value | $152.24B | $10.47B |
Dividend Yield | 4.42% | 2.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Levi Strauss (LEVI) trades at $24.19, down 0.49% on the day, with a neutral technical signal and strong fundamentals. The company reported Q2 2026 EPS of $0.28, beating estimates of $0.24, and raised full-year guidance. Revenue grew 7.6% year-over-year to $1.56B, driven by direct-to-consumer strength. Valuation metrics show a P/E of 17.28 and P/S of 1.45, with robust profitability including a 61.72% gross margin and 9.66% net margin.
Outlook remains positive with 83% analyst buy ratings and a $28 consensus price target, implying 16% upside. Risks include tariff pressures and foreign exchange volatility noted in recent earnings. The dividend was increased to $0.16, supporting income investors. Continued execution on digital strategy and product expansion provides growth catalysts amid competitive apparel markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →
